This article is a correction to:
Arachidonate 15-lipoxygenase-mediated production of Resolvin D5n-3 DPA abrogates pancreatic stellate cell-induced cancer cell invasion
Gabriel A. Aguirre1‡
Michelle R. Goulart1‡Barts Pancreas Tissue Bank1
Jesmond Dalli2*†‡
Hemant M. Kocher1*†‡- 1Centre for Tumour Biology, Barts Cancer Institute, London, United Kingdom
- 2William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, John Vane Science Centre, Queen Mary University of London, London, United Kingdom
A Corrigendum on
Arachidonate 15-lipoxygenase-mediated production of Resolvin D5n-3 DPA abrogates pancreatic stellate cell-induced cancer cell invasion
by Aguirre GA, Goulart MR, Barts Pancreas Tissue Bank, Dalli J and Kocher HM (2023) Front. Immunol. 14:1248547. doi: 10.3389/fimmu.2023.1248547
In the published article, there was an error in the Supplementary Material: Supplementary Methods, Page 7, at the sentence: “Identification was conducted using published criteria, briefly a minimum of six diagnostic ions in total ion count EPI spectrum, matching retention time to synthetic or authentic standards, MRM peaks with more than five data points, a signal-to-noise ratio > 3 (Supplementary Figure 2). [41]. The correct material statement appears below.
“Identification was conducted using published criteria, matching retention time to synthetic or authentic standards, MRM peaks with more than five data points, a signal-to-noise ratio > 3 (UK/MAP). In a subset of samples the identity of these mediators was further confirmed by matching a minimum of six diagnostic ions in total ion count EPI spectrum to that of a reference standard (Supplementary Figure 2). [41]”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: pancreatic ductal adenocarcinoma, specialized pro-resolving mediator, lipid mediator, cancer-associated fibroblast, all-trans retinoic acid, ALOX15, CAF subtypes
Citation: Aguirre GA, Goulart MR, Bank BPT, Dalli J and Kocher HM (2024) Corrigendum: Arachidonate 15-lipoxygenase-mediated production of Resolvin D5n-3 DPA abrogates pancreatic stellate cell-induced cancer cell invasion. Front. Immunol. 15:1353835. doi: 10.3389/fimmu.2024.1353835
Received: 11 December 2023; Accepted: 16 January 2024;
Published: 24 January 2024.
Edited and Reviewed by:
Maarten Fokke Bijlsma, Academic Medical Center, NetherlandsCopyright © 2024 Aguirre, Goulart, Bank, Dalli and Kocher. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hemant M. Kocher, h.kocher@qmul.ac.uk; Jesmond Dalli, j.dalli@qmul.ac.uk
†These authors have contributed equally to this work
‡ORCID: Gabriel A. Aguirre, orcid.org/0000-0003-4125-2661
Michelle R. Goulart, orcid.org/0000-0001-8333-3908
Jesmond Dalli, orcid.org/0000-0001-6328-3640
Hemant M. Kocher, orcid.org/0000-0001-6771-1905